Coeptis Therapeutics, Inc. (NASDAQ:COEP) Struggles with Capital Utilization Compared to Peers

Core Insights - Coeptis Therapeutics, Inc. is facing significant challenges in capital utilization and return generation within the competitive biotechnology sector [1] - The company's Return on Invested Capital (ROIC) is -91.29%, while its Weighted Average Cost of Capital (WACC) is 5.55%, leading to a negative ROIC to WACC ratio of -16.45, indicating inefficiencies in capital utilization [2] - In contrast, ZyVersa Therapeutics, Inc. demonstrates strong capital efficiency with a positive ROIC of 220.45% and a WACC of 7.54%, resulting in a favorable ROIC to WACC ratio of 29.23 [4] Company Comparisons - Cardio Diagnostics Holdings, Inc. has a ROIC of -60.70% and a WACC of 16.84%, yielding a less severe ROIC to WACC ratio of -3.60 compared to Coeptis [3] - SeaStar Medical Holding Corporation and Dermata Therapeutics, Inc. also report negative ROICs of -121.49% and -194.54%, respectively, with ROIC to WACC ratios of -7.04 and -31.71, highlighting similar challenges in generating returns above their cost of capital [5]